Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss

Condition(s) studied

Investigational drug(s) / intervention(s)

HR-pQCT: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body. For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.

pQCT: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.

DEXA: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.

Study summary

The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders. Current methods like DXA scanning have limitations in predicting fracture risks accurately due to their inability to assess cortical and trabecular microstructure. The study emphasizes the importance of evaluating cortical porosity and trabecular volume loss, especially in conditions like post-menopausal osteoporosis and sarcopenia. Additionally, it explores the impact of neurological disorders, renal insufficiency, and endocrinopathies on bone health. Furthermore, the study aims to establish a control group to differentiate pathological changes from age-related variations. Expected outcomes include a comprehensive understanding of bone microarchitecture alterations across various pathologies and the potential to improve fracture risk estimation beyond conventional methods like DEXA scanning. Ultimately, the study anticipates facilitating better management strategies to reduce fracture risks associated with these conditions.

Eligibility

Primary outcome measure(s)

• total volumetric mineral density by HR-pQCT — Day 1
  Describe total volumetric mineral density (mg/ccm HA) as a function of pathologies
• trabecular volumetric mineral density by HR-pQCT — Day 1
  Describe trabecular volumetric mineral density (mg/ccm HA) as a function of pathologies.
• Cortical volumetric mineral density by HR-pQCT — Day 1
  Describe cortical volumetric mineral density (mg/ccm HA) as a function of pathologies.
• Describe number of trabeculae by HR-pQCT — Day 1
  Number of trabeculae (1/mm) as a function of pathologies.
• Trabecular thickness by HR-pQCT — Day 1
  Describe trabecular thickness (mm) as a function of pathologies.
• cortical thickness (mm) by HR-pQCT — Day 1
  Describe cortical thickness (mm) as a function of pathologies.
• trabecular separation by HR-pQCT — Day 1
  Describe trabecular separation (mm) as a function of pathologies.
• cortical porosity by HR-pQCT — Day 1
  Describe cortical porosity (%) as a function of pathologies.

Trial sites (1)

More Centre Hospitalier Universitaire de Saint Etienne trials in France

Other trials for the same condition